Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Citi Resumes Sensei Biotherapeutics (SNSE) at Buy, 'Initial SNS-101 Efficacy Data at ASCO Suggest Early Clinical Activity'
June 3, 2024 2:00 PM EDTCiti analyst Samantha Semenkow resumes coverage on Sensei Biotherapeutics (NASDAQ: SNSE) with a Buy rating and a price target of $4.00.
The analyst comments "We resume coverage after a period of Rating Suspended with a Buy/High Risk rating and $4/shr TP. At ASCO, Sensei... More
